Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

In an effort to better serve our users, we have streamlined our content offering. As a result, we no longer publish new content or update existing content in Lung Cancer. Visit the 'Content & Subscriptions' tab of your Settings page at any time to update your Dashboard or Newsletter Subscription preferences to continue to see news and information that interests you most.

story of the week
Published in Lung Cancer

Journal Scan / Research · September 28, 2022

Pembrolizumab vs Placebo as Adjuvant Therapy for Completely Resected Stage IB–IIIA NSCLC

The Lancet Oncology

 

Additional Info

The Lancet Oncology
Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB-IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial
Lancet Oncol 2022 Sep 09;[EPub Ahead of Print], M O'Brien, L Paz-Ares, S Marreaud, U Dafni, K Oselin, L Havel, E Esteban, D Isla, A Martinez-Marti, M Faehling, M Tsuboi, JS Lee, K Nakagawa, J Yang, A Samkari, SM Keller, M Mauer, N Jha, R Stahel, B Besse, S Peters

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading